相关实验视频
Updated: May 20, 2025

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.7K
卡托基因因通过减轻氧化应激和保护线粒体来改善多克索鲁比诱导的心脏毒性
Hua Zhang1,2, Yunpeng Wang1,2, Rui Wang1,2
1Department of Pediatric Research Institute, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
International journal of molecular sciences
|March 27, 2025
概括
卡尔托根因 (KGN) 在预防多克索鲁比 (DOX) 诱导的心脏毒性方面表现有前途. 这项研究发现,KGN通过减少氧化应激和改善线粒体功能来保护心脏免受DOX损伤.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 多克索鲁比 (DOX) 是一种广泛使用的化疗剂.
- DOX治疗与显著的心脏毒性有关,限制了其临床应用.
- 氧化应激和线粒体功能障碍是DOX诱导心脏毒性 (DIC) 的关键机制.
研究的目的:
- 研究Kartogenin (KGN) 对多克索鲁比诱导心脏毒性 (DIC) 的潜在心脏保护作用.
- 阐明KGN在防止DIC的行动的基本机制.
主要方法:
- 建立DIC的体内和体外模型.
- 评估心脏功能,心肌损伤,氧化应激标志物和线粒体参数.
- 网络药理和RNA测序 (RNA-seq) 的应用,用于机械学研究.
主要成果:
- KGN显著改善了DOX诱导的心力衰竭和心肌损伤.
- 在DIC模型中,KGN治疗减少了氧化应激,并逆转了线粒体功能障碍.
- 机械分析显示,KGN的抗DIC作用与调节氧化应激和线粒体通路密切相关.
结论:
- 卡尔托根因 (KGN) 显示出对多克索鲁比诱导的心脏毒性的显著保护作用.
- KGN的机制涉及减轻氧化应激和维护线粒体平衡.
- KGN代表了一种有前途的治疗策略,用于预防化疗相关的心脏损伤.
相关概念视频
Heart Failure Drugs: Inotropic Agents
476
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
476
Electron Transport Chain: Complex I and II
9.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
Heart Failure Drugs: Diuretics
309
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
309

